Research programme: MBT5 analogs - CohBar
Alternative Names: CB-5046; MBT5 analogs - CohBarLatest Information Update: 28 Feb 2024
At a glance
- Originator Albert Einstein College of Medicine; University of California
- Developer CohBar
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (SC)
- 01 Jul 2020 Research programme: CXCR4 antagonists - CohBar is available for licensing as of 01 Jul 2020. https://www.cohbar.com/